When a genitourinary study misses its enrollment target, the first response is often “we need more outreach.” Sometimes that is exactly right. Sometimes it is an expensive way to push more patients into a workflow that is already losing them.
I have spent nine years in oncology and GU clinical research, including managing Phase I-IV portfolios and serving as study manager and coordinator on investigator-initiated Phase 2 clear cell renal cell carcinoma trials. The pattern I keep returning to is simple: enrollment becomes easier to manage when the site stops treating accrual as one number.
If you only watch the final enrollment count, you learn that the study is behind. You do not learn why.
Clinical trial enrollment is a pathway, not a single metric
A potential participant does not move directly from “patient in clinic” to “enrolled on trial.” The site has to identify the person, prescreen them, confirm eligibility, make a timely approach, support an informed decision, obtain consent, and complete the operational work required to start protocol treatment or procedures.
If a site can produce monthly enrollment totals but cannot quickly answer how many patients were identified, approached, screen-failed, consented, or lost to logistics, the first intervention is measurement—not marketing.
Three places I would look first when a GU trial is not enrolling
1. Eligibility and screen failure
Eligibility criteria are essential to participant safety and scientific validity, but they also define the addressable population. In GU oncology, seemingly small details—laboratory thresholds, prior therapies, timing windows, disease characteristics, comorbidities, or concurrent medications—can sharply reduce the pool.
The practical site question is not “is our screen-failure rate high?” It is “which exact criteria account for the failures we are seeing?” Pull the screen-failure log, group failures by criterion, and look for concentration.
That analysis belongs upstream too. A better clinical trial site feasibility process should pressure-test eligibility against the patients the site actually sees before activation.
2. The patient is identified but never meaningfully approached
A patient who is never approached does not become a screen failure. They simply disappear from the measurable funnel. That makes identification-to-approach one of the most important—and easiest to overlook—site metrics.
Ask who owns the prescreen list. How often is it reviewed? How is the research team notified when an eligible patient appears in clinic? What happens if the coordinator is covering another study? Does the treating physician know which trials are actively looking for participants?
Participant communication matters here as well. In published work on newly diagnosed prostate cancer, my co-authors and I examined understanding of GU terminology and the value of language that better reflects how patients talk about function and treatment. That work reinforced a practical point for me: comprehension is an operating issue, not only a writing issue.
If the explanation is too technical, poorly timed, or disconnected from what the patient is already processing, a technically complete conversation can still fail to create a meaningful decision.
3. The trial is accessible on paper but difficult in real life
Travel, visit frequency, parking, missed work, caregiver demands, treatment timing, long appointment days, and scheduling windows can behave like unwritten eligibility criteria.
Sites should examine these constraints during feasibility and startup, not after enrollment disappoints. Which visits truly require the main site? Where does scheduling create delay? What is the real time from identification to consent? Are participants learning about the trial early enough to consider it without feeling rushed?
When the pathway crosses clinic, research, scheduling, pharmacy, imaging, and other teams, the problem may be a workflow handoff. Our guide to clinical trial site handoffs explains how waiting time between owners can quietly slow both startup and enrollment.
The first three changes I would make
Decompose screen failure by criterion
Review recent screen failures and name the criteria responsible. Look for a small number of rules accounting for a disproportionate share of failures. Bring that evidence into feasibility and sponsor conversations. The point is not to weaken scientifically necessary criteria; it is to understand the population the protocol actually allows.
Make “approach” an owned and measured step
Maintain a standing prescreen list and give each potentially eligible patient a disposition: approached, scheduled for approach, or not approached with a reason. Review that list on a predictable cadence so potential participants do not disappear inside normal clinic workflow.
Model participant burden before activation
Map the visit schedule against the site's catchment area and the participant experience. Identify the visits, timing windows, travel requirements, and operational dependencies most likely to make participation difficult, then decide what can be solved before the study opens.
Four clinical trial enrollment metrics that are more useful than the final total
- Identification-to-approach rate: are potentially eligible patients actually entering a trial conversation?
- Screen failures by criterion: which protocol requirements eliminate the most patients?
- Approach-to-consent rate: is the main loss happening after the trial is explained?
- Time from identification to consent: is the site moving fast enough for the patient's clinical decision timeline?
I would also record why patients decline when that information can be collected appropriately. “Declined” is not a diagnosis. Was the burden too high? Did the patient prefer standard therapy? Was travel unrealistic? Was the trial introduced too late? Did a specific procedure matter?
The goal is not to build another dashboard. It is to make the next operating decision obvious.
When recruitment really is the problem
Sometimes the internal pathway works well and the site simply does not have enough eligible patients. That is a different problem and it may require referral relationships, broader physician awareness, site-network coordination, community outreach, or a sponsor-level discussion about the trial's footprint.
The important thing is to earn that conclusion. If identification, approach, and screening are not measured, “we need more recruitment” is still only a guess.
The takeaway
Low enrollment is a lagging indicator. The transitions move first.
When a site can see identification, screening, approach, consent, and enrollment separately, it can stop treating every enrollment miss as the same problem. That is the point of a site-level diagnostic: find the constraint, change the work around it, and measure whether the pathway improves.
If your study is open but enrollment is not moving as expected, our enrollment and participant pathway work starts with the site's own data rather than a generic recruitment campaign.